First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in China

Renchi Yang, Runhui Wu, Jing Sun, Feifei Sun, Jeremy Rupon, Francois Huard, Joan M Korth-Bradley, Lihong Xu, Binyu Luo, Yingxue Cathy Liu, Pablo Rendo, Renchi Yang, Runhui Wu, Jing Sun, Feifei Sun, Jeremy Rupon, Francois Huard, Joan M Korth-Bradley, Lihong Xu, Binyu Luo, Yingxue Cathy Liu, Pablo Rendo

Abstract

Background: Nonacog alfa (recombinant factor IX [FIX]) is approved in China for the control and prevention of bleeding events in patients with hemophilia B. This was the first study to assess prophylaxis and on-demand therapy with recombinant FIX replacement in a real-world setting in China. This study aimed to evaluate the safety and efficacy of nonacog alfa in Chinese patients with hemophilia B.

Methods: In this open-label, multicenter study (clinicaltrials.gov identifier NCT02336178), patients received on-demand or prophylactic treatment with intravenous nonacog alfa for approximately 6 months or 50 exposure days, whichever occurred first. The primary safety outcome was medically important events (i.e., development of FIX inhibitors, allergic reactions, and thrombotic events). Key secondary efficacy outcomes included the annualized bleeding rate for on-demand treatment and prophylaxis, response to on-demand treatment, the number of infusions per bleeding event, and the number of breakthrough bleeding events within 48 hours of prophylaxis.

Results: Seventy male patients (mean [standard deviation] age 7.8 [7.2] years) were enrolled (on-demand, n = 37; prophylaxis, n = 57 [24 patients were included in both groups]). Thirty-eight (54%) patients had up to 50 FIX exposure days before the study. The only medically important event was a transient low-titer FIX inhibitor (incidence 1.4%, 95% confidence interval, 0-7.7). The mean annualized bleeding rate was 26.3 for on-demand treatment and 6.5 for prophylaxis. A mean (standard deviation) of 1.5 (1.7) nonacog alfa infusions were given per bleeding episode; 78.8% of episodes resolved with 1 infusion. Response was "excellent" or "good" for 88% of the on-demand infusions. Twenty-three bleeding events (n = 11 patients) occurred within 48 hours of 2032 prophylaxis doses (1.13%).

Conclusion: In the real-world setting, nonacog alfa is safe and effective for on-demand treatment and for prophylaxis for patients with hemophilia B in China.

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Figures

Figure 1
Figure 1
Patient disposition. ∗Patients who received at least 1 dose of on-demand or prophylactic treatment; 24 patients alternated between on-demand and prophylaxis regimens and were included in both groups.

References

    1. Franchini M. Current management of hemophilia B: recommendations, complications and emerging issues. Expert Rev Hematol 2014;7:573–81.
    1. Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 2012;379:1447–56.
    1. Katz J. Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey. Haemophilia 1996;2:28–31.
    1. White GC, Rosendaal F, Aledort LM, et al. . Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001;85:560.
    1. Qu Y, Nie X, Yang Z, et al. . The prevalence of hemophilia in mainland China: a systematic review and meta-analysis. Southeast Asian J Trop Med Public Health 2014;45:455–66.
    1. Novo Nordisk Haemophilia Foundation Report 2007/2008. Zurich, Switzerland: Novo Nordisk Haemophilia Foundation; 2008.
    1. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. . Guidelines for the management of hemophilia. Haemophilia 2013;19:e1–47.
    1. Franchini M, Frattini F, Crestani S, Bonfanti C. Haemophilia B: current pharmacotherapy and future directions. Expert Opin Pharmacother 2012;13:2053–63.
    1. Guidelines for the Management of Hemophilia. 2nd ed. 2012. Available at: (accessed: June 19, 2020).
    1. World Federation of Hemophilia Report on the Annual Global Survey 2015. Montreal, QC, Canada: World Federation of Hemophilia; 2016.
    1. BeneFIX [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc. (Pfizer); 2015.
    1. Bei Fu BeneFIX [package insert]. Beijing, China: Wyeth Farma; 2016.
    1. Yang R, Zhao Y, Wang X, et al. . Evaluation of the safety and efficacy of recombinant factor IX (nonacog alfa) in minimally treated and previously treated Chinese patients with haemophilia B. Haemophilia 2012;18:e374–8.
    1. Rendo P, Smith L, Lee H-Y, Shafer F. Nonacog alfa: an analysis of safety data from six prospective clinical studies in different patient populations with haemophilia B treated with different therapeutic modalities. Blood Coagul Fibrinolysis 2015;26:912–8.
    1. Hua B, Wu R, Sun F, et al. . Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia B. Thromb Haemost 2017;117:1052–7.
    1. Valentino LA, Rusen L, Elezovic I, Smith LM, Korth-Bradley JM, Rendo P. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia 2014;20:398–406.
    1. Kavakli K, Smith L, Kuliczkowski K, et al. . Once-weekly prophylactic treatment versus on-demand treatment with nonacog alfa in patients with moderately severe to severe hemophilia B. Haemophilia 2016;22:381–8.
    1. Lambert T, Recht M, Valentino LA, et al. . Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia 2007;13:233–43.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する